- Home
- RYN vs CPRX Comparison
RYN vs CPRX Comparison
Compare RYN & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$21.71
N/A
Current Price
$24.16
Company Overview
Basic Information| Metric | RYN | CPRX |
|---|---|---|
| Founded | 1926 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 1994 | 2006 |
Fundamental Metrics
Financial Performance| Metric | RYN | CPRX |
|---|---|---|
| Price | $21.71 | $24.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $26.00 | ★ $33.25 |
| AVG Volume (30 Days) | ★ 3.5M | 1.1M |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 11.34% | N/A |
| EPS Growth | 26.78 | ★ 107.94 |
| EPS | ★ 3.03 | 1.27 |
| Revenue | ★ $484,485,000.00 | $119,072,803.00 |
| Revenue This Year | N/A | $19.98 |
| Revenue Next Year | $2.96 | $6.96 |
| P/E Ratio | ★ $7.64 | $18.93 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $21.06 | $19.05 |
| 52 Week High | $28.31 | $26.56 |
Technical Indicators
Market Signals| Indicator | RYN | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 49.91 |
| Support Level | $21.22 | $22.25 |
| Resistance Level | $22.57 | $24.63 |
| Average True Range (ATR) | 0.55 | 0.78 |
| MACD | -0.13 | -0.07 |
| Stochastic Oscillator | 4.55 | 38.26 |
Price Performance
Historical Comparison RYN
CPRX
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).